Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update

Bibliography

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society: Just the facts. 2007-2008. Available from: http://www.nationalmssociety.org/ about-multiple-sclerosis/FAQs-about-MS/index.aspx#howmany. [Accessed 26 October 2009]
   Google Scholar
• Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-38
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS, The European Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-97
   PubMed Web of Science ®Google Scholar
• Ebers G, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
   PubMed Web of Science ®Google Scholar
• The IFNb Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C, Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-59
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Sela M. Poly(a-amino acids) – From a better understanding of immune phenomena to a drug against multiple sclerosis. Acta Polym 1998;49:523-25
   Google Scholar
• Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 2007;79:537-70
   PubMed Web of Science ®Google Scholar
• Varkony H, Weinstein V, Klinger E, The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother 2009;10(4):657-68
   PubMed Web of Science ®Google Scholar
• De Stafano N, Filippi M, Confavreux C, The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler 2009;15:238-43
   PubMed Web of Science ®Google Scholar
• PrimeNewswire, Inc. Momenta Pharmaceuticals Announces Filing of Abbreviated New Drug Application With a Paragraph IV Certification for Generic Version of Copaxone. Press release, 11 July 2008, Cambridge, MA. Available from: http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=320978. [Accessed 26 October 2009]
   Google Scholar
• Sigma Aldrich Catalog. Available from: http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/P1152
   Google Scholar
• Natco Pharma Limited. NATCO collaborates with Mylan for glatiramer acetate. Available from: http://www.natcopharma.co.in/NewsDetails.aspx?id=25. [Accessed 19 March 2010]
   Google Scholar
• Miller D, Barkhof F, Montalban X, Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-88
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold FC, National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11
   PubMed Web of Science ®Google Scholar
• Korn T, Oukka M, Kuchroo V, Betelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007;19:362-71
   PubMed Web of Science ®Google Scholar
• Kebir H, Ifergan I, Alvarez JI, Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009;66:390-402
   PubMed Web of Science ®Google Scholar
• Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 2004;24(2):111-28
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol 2008;195(1-2):140-45
   PubMed Web of Science ®Google Scholar
• Ifergan I, Kebir H, Bernard M, The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008;131:785-99
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S. Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacol Ther 2003;98:245-55
   PubMed Web of Science ®Google Scholar
• Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 cells and regulatory T cells. J Clin Immunol 2008;28:660-70
   PubMed Web of Science ®Google Scholar
• Saresella M, Marventano I, Longhi R, CD4+CD25+FoxP3+PD1 – regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 2008;22:3500-8
   PubMed Web of Science ®Google Scholar
• Nikbin B, Mohyeddin Bonab M, Khosravi F, Role of B cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:13-42
   PubMed Web of Science ®Google Scholar
• Valenzuela RM, Costello K, Chen M, Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007;13:754-62
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Broekmans T, Natural naive CD4+CD25+ CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-20
   PubMed Web of Science ®Google Scholar
• Copaxone® (glatiramer acetate injection) prescribing information. Teva Pharmaceuticals USA, Inc., North Wales, PA. Rev 2/2009
   Google Scholar
• Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008;225:26-36
   Google Scholar
• Teitelbaum D, Meshorer A, Hirshfeld T, Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-48
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Webb C, Bree M, Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic copolymer. Clin Immunol Immunopathol 1974;3:256-62
   PubMedGoogle Scholar
• Krull I, Cohen S. The complexity of glatiramer acetate and the limits of current multidimensional analytical methodologies in the attempt to characterize the product. Letter in reference to Citizen Petition FDA-2008-P-0529 to the Dockets Management Branch, Food and Drug Administration. 16 January 2009
   Google Scholar
• Aharoni R, Kayhan B, Eilam R, Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. PNAS 2003;100:14157-62
   PubMed Web of Science ®Google Scholar
• Kala M, Rhodes SN, Piao W-H, B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010;221:136-45
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Brenner T, Abramsky O, Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003;9:592-99
   PubMed Web of Science ®Google Scholar
• Brenner T, Arnon R, Sela M, Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-60
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmieid MC, Cook SL, Glatiramer acetate (Copaxone) induces degenerate Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105:967-76
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Teitelbaum D, Gurevich E, Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells—specificity and promiscuity. PNAS 1994;91:4872-76
   PubMed Web of Science ®Google Scholar
• Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. PNAS 2004;101:14593-98
   PubMed Web of Science ®Google Scholar
• Ragheb S, Abramczyk S, Lisak D, Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult Scler 2001;7:43-7
   PubMed Web of Science ®Google Scholar
• Chen M, Conway K, Johnson KP, Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for 6 years. J Neurol Sci 2002;201:71-7
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Farina C, Yassouridis A, Multiple sclerosis: comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. PNAS 2000;97:7452-57
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Leitner O, Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. PNAS 2000;97:11472-77
   PubMed Web of Science ®Google Scholar
• Hestvik ALK, Skorstad G, Price DA, Multiple sclerosis: glatiramer acetate induced anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008;14:749-58
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichman H, Schneider H. Presence of glatiramer acetate-specific TH2 cells in the cerebrospinal fluid of patients with multiple sclerosis 12 months after the start of therapy with glatiramer acetate. J Neurodegeneration Regen 2008;1:19-22
   Google Scholar
• Begum-Haque S, Sharma A, Kasper IR, Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 2008;204:68-5
   Google Scholar
• Hong J, Li N, Zhang X, Induction of CD4+CD25+ regulatory T cells by copolymer-1 through activation of transcription factor Foxp3. PNAS 2005;102:6449-54
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Domev H, The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. PNAS2005:102:19045-50
   PubMed Web of Science ®Google Scholar
• Aharoni R, Herschkovitz A, Eilam R, Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. PNAS 2008;105:11358-63
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod'homme T, Youssef S, Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43
   PubMed Web of Science ®Google Scholar
• Liu J, Johnson TV, Lin J, T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 2007;37:3143-54
   PubMed Web of Science ®Google Scholar
• Weber MS, Starck M, Wagenpfeil S, Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004;127:1370-78
   PubMed Web of Science ®Google Scholar
• Ruggieri M, Pica C, Lia A, Combination treatment of glatiramer acetate and minocycline affects phenotype expression of blood monocyte-derived dendritic cells in multiple sclerosis patients. J Neuroimmunol 2008;197:140-46
   PubMed Web of Science ®Google Scholar
• Begum-Haque S, Sharma A, Christy M, Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;219:47-53
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-08
   PubMed Web of Science ®Google Scholar
• Boneschi FM, Rovaris M, Johnson KP, Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled trials. Mult Scler 2003;9:349-55
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Rocca MA, Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 2001;57:731-33
   PubMed Web of Science ®Google Scholar
• Khan O, Shen Y, Bao F, Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term 1H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008;18:314-19
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bruzzi P, Comi G, The distribution of magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler 2005;11:447-49
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP, A prospective open-label study of glatiramer acetate: over a decade of continuous use in MS patients. Mult Scler 2006;12:309-20
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurol Sci 2005;26:S183-86
   PubMed Web of Science ®Google Scholar
• Kornek B, Bernert G, Balassy C, Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003;34:120-26
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. PNAS 1999;96:3842-47
   PubMed Web of Science ®Google Scholar
• Filippi M, Wolinsky JS, Comi G, the CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006;5:213-20
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-4
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003;9(6):585-91
   PubMed Web of Science ®Google Scholar
• Comi G, Martinielli V, Redegher M, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O'Connor P, Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
   PubMed Web of Science ®Google Scholar
• Weindl H, Hohlfeld R. Multiple sclerosis therapeutics. Unexpected outcomes clouding undisputed success. Neurology 2009;72:1008-15
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58:S3-9
   PubMed Web of Science ®Google Scholar
• Gold R. Combination therapies in multiple sclerosis. J Neurol 2008;255:51-60
   PubMed Web of Science ®Google Scholar
• Lublin F, Cutter G, Elfont R, A trial to assess the safety of combining therapy with interferon b-1a and glatiramer acetate in patients with relapsing MS [abstract]. Neurology 2001;56:A148
   PubMedGoogle Scholar
• Lublin F, Baier M, Cutter G, Results of the extension of a trial to assess the longer term safety of combining interferon beta 1-a and glatiramer acetate [abstract]. Neurology 2002;58:A85
   PubMedGoogle Scholar
• A multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either drug alone in patients with relapsing-remitting multiple sclerosis (CombiRx). Available from: http://www/clinicaltrials.gov/ct2/ show/NCT00211887?term= Multiple+Sclerosis&rank=9. [Accessed 13 November 2009]
   Google Scholar
• Goodman AD, Rossman H, Bar-Or A, GLANCE. Results of a phase 2 randomized, double-blind, placebo-controlled study. Neurology 2009;72:806-12
   PubMed Web of Science ®Google Scholar
• Vollmer T, Panitch H, Bar-Or A, Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-70
   PubMed Web of Science ®Google Scholar
• Arnold DL, Campagnolo D, Panitch H, Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008;255:1473-78
   PubMed Web of Science ®Google Scholar
• O'Connor P, Filippi M, Arnason B, 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing remitting multiple sclerosis: a prospective randomized multicentre study. Lancet Neurol 2009;8:889-97
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, Efficacy of treatment with IFNB-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009;26:552-62
   PubMed Web of Science ®Google Scholar
• Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoeconomics Outcomes Res 2009;9(3):205-14
   PubMedGoogle Scholar
• Bell C, Graham J, Earnshaw S, Cost-effectiveness of four immunomodulatory therapies for relapsing remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manage Care Pharm 2007;13:245-61
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manage Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009;277:S37-41
   PubMed Web of Science ®Google Scholar
• Metz LM, Patten SB, Archibald CJ, The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004;75:1045-47
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Hoffman J, Apfel R, Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Quality Life Outcomes 2008;6:67
   PubMed Web of Science ®Google Scholar
• Pollock C, Wayne Johnson D, Horl WH, Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008;3:193-99
   PubMed Web of Science ®Google Scholar
• Deraos G, Chatzantoni K, Matsoukas M-T, Citrullination of linear and circular altered peptide ligands from myelin basic protein (MBP87-99) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. J Med Chem 2008;51:7834-42
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H, Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-82
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N, Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75
   PubMed Web of Science ®Google Scholar
• Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001;79:552-65
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Murialdo A, Drago F, Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000;247:220-21
   PubMed Web of Science ®Google Scholar
• Aharoni R, Brenner O, Cohen A, The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease—dextran induced colitis. Int Immunopharmacol 2008;8:1578-88
   PubMed Web of Science ®Google Scholar